Hereditary angioedema type I (HAE-CI-INH) is an inherited disorder characterized by repeated severe angioedema attacks mostly triggered by traumas, emotional stress, increased estrogen levels or surgical procedures, in particular, odontostomatological interventions. Icatibant, a bradykinin B2 receptor antagonist, has been approved for treatment of HAE attacks. In this paper we describe the "off label" administration of icatibant as short-term prophylaxis of dental extraction in a patient with HAE with the aim of preventing perioperative angioedema attacks. The drug showed an effective and safe profile. Thus, a short-term prophylaxis of angioedema attacks in patients with HAE may be arranged on a multidisciplinary basis, according to the clinical history of each single patients.
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Type I hereditary angioedema (HAE-C1-INH) is a pathological condition characterized by reduced circulating levels and activity of C1 esterase inhibitor (Cl-INH); these defects encompass up to 85% of primitive cases (1) . Clinical manifestations of the disease include non-itchy recurrent episodes of oedema in subcutaneous and submucosal tissues. Oedematous areas are usually limited and ubiquitous in the body; oedema attacks may rapidly progress even to exitus, in case of laryngeal swelling (2) . Precipitating conditions include traumas, infections, emotional stress, and increased oestrogen levels (3) (4) (5) (Table I) . Odontostomatological procedures, usually regarded as minor surgical and anesthesiological interventions, may trigger severe life-threatening angioedema attacks due to the continuity and contiguity of involved structures with the upper respiratory tract (6) .
Angioedema attacks may cause severe respiratory complications, including aspiration, asphyctic crisis and death (7) . Exitus has been reported to occur in up to 25% of cases (8) .
Icatibant is a highly selective antagonist of bradykinin receptor-2; bradykinin is the key player in the humoral pathway leading to angioedema. Administration of icatibant has been approved by European drug agencies for acute HAE-Cl-INH attacks (9, 10) . In this case report, we describe the administration of icatibant as short-term prophylaxis of a dental procedure under analgo-sedation in a patient affected by HAE type 1. The patient gave written informed consent. 
Clinical case
A 45-year-old woman with American Society of Anesthesiologists physical status II, and body mass index of 24 kg/m2, came under anaesthesiological observation before avulsion of 47 due to pulpitis and odontogenic abscess. Seven days previously, the patient had been admitted to hospital due to severe dyspnea and syncope; the symptoms occurred within two hours after oral administration of rovamycin (3.000.000 IV), prescribed by her general practitioner (GP).
The patient had been previously diagnosed with HAE type I. In her family history, a maternal uncle had suffered from recurrent angioedema attacks, and a niece was currently under investigation for similar episodes. In her childhood, the patient had suffered from repeated angioedema attacks characterized by abdominal pain and even glottis oedema; these episodes were mostly triggered by antibiotic administration. In the following years, the patient had been repeatedly admitted to the emergency department due to severe angioedema attacks; episodes were alternatively triggered by insect bites, drugs other than antibiotics, such as metoclopramide and dental procedures. Type I HAE-CI-INH was finally diagnosed when the patient was 30 years old. Chronic treatment with androgens (danazol 200 mg standard dose) was then started as preventive therapy; administration of blood-derived c1-inhibitor was limited to acute attacks. The most recent angioedema attacks were reported by the patient after moderate physical activity, emotional stress and dental procedures. For this reason, subsequent dental procedures were carried out under general anaesthesia and long-term prophylaxis with danazol. As the patient developed autoimmune type I hepatitis and primary biliary cirrhosis syndrome, danazol was reduced to 50 Forty-five minutes before dental procedure, after an informed consent was obtained by the patient, cardiovascular parameters were non-invasively monitored: non-invasive blood pressure (NIBP), electrocardiogram (ECG), and oxygen saturation (Sp02)' and a valid intravenous access was prepared. According to a schedule previously arranged by the immunologist, internist and anaesthesiologist a subcutaneous dose of icatibant (30 mg) was administered: the drug was devoid of systemic hemodynamic effects or local effects such as pain or rush. After 45 minutes, sedation was induced (midazolam 1.5 mg and fentanyl 150 meg) in the operating room (OR) and oxygen therapy (3 lImin) administered in spontaneous breathing. Devices for cardio-respiratory resuscitation and difficult airway management (videolaringoscope, Frova introducer, cricoidectomy kit) had been prearranged as well as drugs for acute angioedema attacks, including plasma C-l derivative, fresh frozen plasma, and tranexamic acid. Once an adequate level of analgosedation had been obtained, the surgeon proceeded to troncular anaesthesia with mepivacaine 1% (54 mg). Overall, the dental procedure lasted 30 minutes. During this period, no symptoms of angioedema occurred; post-operative recovery was regular, and no cardio-respiratory complications were observed. After procedure, complement fraction C3 value was 99 mg/dl, C4 was 9 mg/dl, Cl inhibitor 13 mg/dl, Factor XII 99% and total IgE 67.80 kUAIl. In the immediate post-operative period, no further doses of icatibant, cortisol or antihistaminic compounds were required. Analgesia was obtained by intravenous administration of morphine (10 mg bolus) and paracetamol 1000 mg. The patient was monitored for the following eight hours and was discharged in the afternoon ofthe same day. At that time, an additional preventive dose of icatibant (30 mg) was given to the patient. The patient, contacted by phone calls in the following 12,24 and 48 hours, did not report any episode of angioedema or initial oedema of oropharingo-laringeal areas; additional administrations of icatibant were not needed.
DISCUSSION
Type I HAE-CI-INH is an inherited disease with autosomal dominant transmission, characterized by a mutation of C1 esterase inhibitor gene and reduced activity of Cl inhibitor (CI-INH). In normal conditions, CI-INH inhibits both Cl-r and C I-s components of complement as well as activated Factor XII of the coagulation cascade, which increases bradykinin levels by converting pre-callicreine in callicreine. Bradykinin has a key role, as it is the link between the coagulation and inflammation cascade. Thus, CI-INH, by inhibiting activated Factor XII, may prevent the vasoctive and angioedema facilitating effect bradykinin.
Icatibant is a selective antagonist of bradykinin receptor type B2, and its clinical use has been approved by European drug agencies since 2008 (11) . The drug has a safety profile and is effective for treatment of severe angioedema attacks (12) . Recent international guidelines strongly recommend a short-term prophylaxis with icatibant in patients with medical history of angioedema attacks, in particular before dental or oral surgical procedures (13) .
Therapeutic agents recommended by World Allergy Organization (WAO) (13) for short-term prophylaxis include concentrated CI-INH at 10-20 U/kg or 1000 U from 1 to 6 hours before the procedure or attenuated androgens. In particular, danazol (2.5-10 mglkg/dl) should be administered 5 days before surgery and 2-5 days after-surgery. The choice of drug for prophylaxis treatment in HAE patients should be based on:
-frequency of angioedema attacks; -site of oedema; -severity of attacks; -interference of the disease on patient's quality of life.
In HAE patients, a short-term prophylaxis in the pre-medication stage, about 45 minutes before surgical procedure, is recommended. It should be pointed out, however, that pre-operative prophylaxis will not eliminate the risk of angioedema attacks during surgical procedure (14, 15) . The risk of perioperative angioedema in patients with HAE type I-II undergoing surgical procedures without pharmacological prophylaxis has been recently estimated to range from 5.7% to 30.5% (16) . The unpredictable nature of HAE episodes supports current international recommendations that a shortterm prophylaxis should be considered based on clinical characteristics ofindividual patients. Current international guidelines do not recommend icatibant for short-term prophylaxis; only anecdotal cases have been reported on this topic (17) (18) (19) (Table II) . 'For this reason, the procedure should be performed in a safe environment, where drugs for acute angioedema attacks (icatibant, Cl-inhibitor complex, plasma, tranexamic acid) are immediately available. The present case report indicates that icatibant is safe and effective in the short prophylaxis of a patient with a diagnosis of HAE-CI-INH confirmed by clinical and laboratory data. The patient who underwent a surgical procedure of dental avulsion with potential risks and complications had a major benefit from the "off label" administration of the bradykinin B2 receptor antagonist.
Icatibant, indeed, allowed to manage the surgical procedure in the HAE patient under day-hospital standard conditions, as in normal subjects. It should be pointed out that the patient was also affected by severe autoimmune hepatitis; the link between HAE-C1-INH and autoimmune diseases has been previously hypothesized by Nielsen et al. (20) . The authors described a peculiar non-IgE mediated hyper-reactivity of mast cells in some patients with autoimmune and idiopathic HAE-C1-INH (20) .
Comorbid conditions, such as hepatitis, may contraindicate danazol for preventive treatment. Bradykinin B2 receptor antagonist has been reported to be tolerated also in patients with chronic hepatic diseases (21) . Compared to icatibant, Cl-inhibitor (Cl-INH) complex for prophylactic and therapeutic use is more invasive, as it requires an intravenous route and has been reported to be less effective in patients with severe angioedema attacks, probably because of an immuno-mediated resistance to C1-INH derivative (21) . Additional disadvantages of human plasma-derived C1-INH are the degree of purification and high costs (22, 23) . Similar risks are associated to the infusion of human plasma-derived C1-INH, Cl-INH recombinant and fresh plasma. In particular, the potential risks of autoimmune hepatic disease and allergic reactions associated to the administration of androgens, ecallantide and haemoderivatives should be considered (Table III) (24, 25) .
In the present case, a short-term premedication with icatibant turned out to be safe and effective in the presence of multiple comorbid conditions and was well accepted by the patient. The bradykinin B2 receptor antagonist, indeed, has been reported to have a favourable safety and efficacy profile for treatment of severe attacks of HAE type I (12, 26) . Administration of icatibant as short-term premedication, 45 min before dental surgery, allowed us to proceed to analgo-sedation in spontaneous breathing, contrary to cases previously reported in literature (18) . This allowed us to carry out the procedure in the ambulatory setting, like minor surgical interventions, but at the same time to proceed according to guidelines and guarantee emergency interventions in case of severe complications. The first case reported in the literature of bradykinin B2 receptor antagonist use in short-term prophylaxis, referred to a procedure of fine-needle aspiration and biopsy (FNAB) of the thyroid gland, and had an excellent therapeutic outcome (19) .
In 2011, two patients affected by HAE Type II who underwent head and neck surgical procedures have been reported (17) . Finally, in 2012, a young woman was successfully treated with icatibant 30 mg as premedication before molar tooth extraction (18) . In this last report, the patient was younger, in better clinical conditions than our patient, without the immuno-hepatologic complications observed in our case; the patient was treated after deep analgosedation and with the placement of a laryngeal mask (18) . In all cases reported in the literature, the only collateral effect of icatibant administration was a tolerable itch and reddening of the area of injection, which rapidly healed. Considerations about safety, collaboration, and satisfaction of the patient were of major importance in the choice of icatibant for short-term premedication. The simple route of administration of the bradykinin B2 antireceptor, its proved efficacy, tolerability and clinical safety, are all characteristics which contribute to reduce preoperative and postoperative stress and complications. As recently highlighted by Gower (27) , optimal HAE treatment should be based on specific needs of the patient, and/or on consideration of short-and long-term prophylaxis. Patients with HAE may differ from each other, depending on the characteristics and number of angioedema attacks, type ofjobs, facility in reaching the first aid location and/or healthcare operators, comorbidities, cost! benefit ratio and, last but not least, the patient's preferences. Thus, treatment of HAE requires a multidisciplinary approach targeted on each single patient's needs (27) .
Administration of the bradykinin B2 receptor antagonist icatibant as short-term prophylaxis remains "off label", although this compound has been shown to improve perioperative care in difficult cases, such as in patients with HAE type I. Critical conditions, such as severe angioedema attacks, should be managed with effective pharmaceutical interventions in a safe medical setting in order to guarantee vital support to patients. This may prevent severe complications related to the administration of haemoderivatives, hepatotoxic effects of attenuated androgens or poor efficacy of non-selective pharmacological agents. The schedule not only allows to carry out odontostomatological procedures in the ambulatory setting, after prophylaxis and premedication have been administered at home, but also improves therapeutic efficacy and patient's satisfaction. Moreover, administration of an analgosedation while the patient is spontaneously breathing may prevent the risks related to traumatic manoeuvres such as orotracheal intubation (28) . Our experience suggests that a specific drug may prevent collateral effects in patients at high risk of life-threatening events even during minor invasive procedures. It is highly desirable that recommendations/guidelines regarding therapeutic indications of bradykinin B2 receptor antagonist for short-term prophylaxis of RAE type I should be revised, and randomized controlled trials should be planned to test the clinical efficacy of bradykinin B2 receptor antagonist icatibant in short-term prophylaxis.
